Q-omics provides the consensus-scored LHFPL1 profile across patient tissues and cancer cell-line models. LHFPL1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LHFPL1 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, LHFPL1 RNA expression shows 16,236 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, THCA, and TGCT as cancer lineages where LHFPL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LHFPL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LHFPL1 survival associations across molecular data types. LHFPL1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LHFPL1 RNA expression–survival associations across cancer types. High LHFPL1 expression shows unfavorable associations in READ, MESO and BLCA, but favorable associations in LUAD, CESC and PAAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify LUAD as the clearest survival context for LHFPL1 RNA expression.
This table summarizes LHFPL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LHFPL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LHFPL1 shows lower tumor expression in THCA, COAD, BRCA, HNSC and KIRC and higher tumor expression in LUSC. The THCA box plot shows higher LHFPL1 RNA expression in normal versus tumor tissue (log2 FC = −0.845, t-test p < 0.001).
This table shows molecular features associated with LHFPL1 in patient tissues and cancer cell lines. In patient samples, LHFPL1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LHFPL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
